Apimeds Pharmaceuticals US, Inc.
APUSNYSEAMERICANHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 15, 2026 close
- Market cap
- $7.52M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.95$23.40
- Volume (live)
- -
- Avg. volume (3M)
- 7.67M
Apimeds Pharmaceuticals US (APUS) Stock Price & Financial Analysis
Apimeds Pharmaceuticals US Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $4.00 - $4.23 |
|---|---|
| 52-Week High | $23.40 |
| 52-Week Low | $0.95 |
| Open | $4.12 |
| Volume (last close) | 109.73K |
| Average Volume (3M) | 7.67M |
| 50-Day MA | $3.97 |
|---|---|
| 200-Day MA | $5.01 |
| 1-Year Change | +138.59% |
| Market Cap | 7.52M |
|---|---|
| Shares Outstanding | 1.71M |
| Price to Book (P/B) | 0.07 |
| EV/EBITDA | -0.62 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Apimeds Pharmaceuticals US at a Glance
As of the Oct 15, 2026 close, Apimeds Pharmaceuticals US (APUS) has a market capitalization of $7.52M.
As of its latest reported balance sheet, it holds $278.37K in cash and securities against $14.58M of debt, a net debt position of $14.30M.
Apimeds Pharmaceuticals US does not currently pay a dividend.
The share price is up 138.6% over the past year. At $4.39 (the Oct 15, 2026 close) it sits within its 52-week range of $0.95 to $23.40, below its 200-day moving average of $5.01.
Frequently Asked Questions About Apimeds Pharmaceuticals US
What is the current stock price for APUS?
As of the Oct 15, 2026 close, APUS stock trades at $4.39. The 52-week range is $0.95–$23.40, with a day range of $4.00–$4.23.
What is the P/E ratio for APUS?
The P/E ratio (Price-to-Earnings) for APUS is shown in the Key Statistics section. This valuation metric helps compare Apimeds Pharmaceuticals US, Inc. to industry peers.
Does APUS pay dividends?
Apimeds Pharmaceuticals US does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for APUS?
Analyst ratings and recommendations for APUS are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of APUS?
As of the Oct 15, 2026 close, Apimeds Pharmaceuticals US's market capitalization is $7.5M, classifying it as a micro-cap company. Apimeds Pharmaceuticals US operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.